A5027378939- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Hemodynamic Monitoring and Therapy
- Heart Failure Treatment and Management
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Cardiac Imaging and Diagnostics
- Pharmaceutical Practices and Patient Outcomes
- COVID-19 epidemiological studies
- Ultrasound in Clinical Applications
- Vaccine Coverage and Hesitancy
- Bioinformatics and Genomic Networks
- Radiomics and Machine Learning in Medical Imaging
- SARS-CoV-2 and COVID-19 Research
- Ferroptosis and cancer prognosis
- Neuroblastoma Research and Treatments
- Liver Disease Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Landslides and related hazards
- Cancer Diagnosis and Treatment
- Rock Mechanics and Modeling
- Geotechnical Engineering and Analysis
- Non-Invasive Vital Sign Monitoring
National University Health System
2025
National University of Singapore
2025
Xiangyang Central Hospital
2023-2024
Kaohsiung Veterans General Hospital
2024
Shenzhen International Travel Health Care Center
2024
Guangzhou University
2023
Shanghai Chest Hospital
1988-2017
Shanghai Pulmonary Hospital
2006
Chinese University of Hong Kong
2006
Guangdong Provincial People's Hospital
2006
Numerous computational drug repurposing methods have emerged as efficient alternatives to costly and time-consuming traditional discovery approaches. Some of these are based on the assumption that candidate should a reversal effect disease-associated genes. However, such not applicable in case there is limited overlap between disease-related genes drug-perturbed In this study, we proposed novel Drug Repurposing method Inhibition Effect gene regulatory network (DRIE) identify potential drugs...
To investigate the impact of vaccines on sociodemographic characteristics, clinical profiles, and outcomes SARS-CoV-2 infection among healthcare workers in South China during period Omicron variant dominance, a retrospective, analytical cross-sectional study was conducted. The findings revealed that while full vaccination could not prevent efficiently (26.51% uninfected vs 14.29% between vaccinated unvaccinated participants, p = 0.506), it did substantially reduce length viral clearance...
Abstract Objective This study aimed to develop and validate a predicting model for risk of rehospitalization within 30 days post discharge in patients diagnosed with Heart Failure Preserved Ejection Fraction (HFpEF). Methods Clinical data 9555 HFpEF registered the heart failure registry from 2014 2022 at our hospital were analyzed. A total 8160 (from 2014-2021) designated as training set, 1395 2022) validation set. predictive was established based on factors associated 30-day due identified...
Abstract Background The identification of risk factors for all-cause mortality in patients diagnosed with heart failure mildly reduced ejection fraction (HFmrEF) and exhibiting varying post-discharge left ventricular (LVEF) patterns remains incomplete. This study aimed to determine the independent among HFmrEF different LVEF variation post-discharge. Methods retrospective analyzed data from 807 admitted our hospital between January 2015 August 2020. Patients were categorized into three...
Abstract Background The identification of independent risk factors for left ventricular ejection fraction (LVEF) deterioration is clinical importance in patients diagnosed heart failure with mildly reduced (HFmrEF). This study aimed to determine the LVEF post discharge among hospitalized HFmrEF patients. Methods retrospective analyzed data from 807 admitted our hospital between January 2015 and August 2020. values were assessed by echocardiography 6 months 1 year after discharge. Patients...
Abstract Background Prognostic prediction for heart failure with mildly reduced ejection fraction (HFmrEF) patients remains challenging. We aimed to create and validate a mortality risk model HFmrEF at 6-month, 1-year, 3-year post discharge. Methods Clinical data of 1691 registered in the registry from 2015 2020 Heart Center our hospital were analyzed. Patients assigned into training (1183 patients) validation cohort (508 7:3 ratio. Predictive variables various period discharge identified by...
Background: Predicting in-hospital cardiac arrest (IHCA) is crucial for preventing patient fatalities. However, it remains challenging due to the irregularities in time series data across various features. Previous studies relied on traditional medical scoring systems, but their accuracy was limited as models were overly simplistic. Recent research using machine learning methods has shown improved results. In our work, we employ deep and approaches, which are considered most powerful...
Introduction: Angiogenesis is one of the hallmarks cancer and can impact processes initiation, progression, response to therapy. Background: Anti-angiogenic therapy thus an encouraging therapeutic option treat cancers, but detailed angiogenic mechanisms association between angiogenesis clinical outcome remain unknown in different cancers. Methods: Here, we systematically assess impacts 82 angiogenesis-associated genes (AAGs) tumor tissue specificity prognosis across 16 types. Results:...
17079 Background: Recent phase II study (S9504) showed that 3 cycles of consolidation docetaxel after C-RT is associated with prolonged survival but 6 pts (7%) had severe (≥gr 3) radiation pneumonitis and 2 (2.4%) died.(None at S9019) LCRG, a multinational Asian group, designed randomized aiming to assess the treatment outcomes GEM or GEM/Carboplatin (CAR) C-RT. potent sensitizer known recall phenomena, thus we evaluated risk GEM-based chemotherapy in this interim report. Methods: Enrollment...
Abstract Background The prognostic impact of lung ultrasound derived B-Line (LU-BL) in heart failure patients with mildly reduced left ventricular ejection fraction (HFmrEF) remains elusive. We evaluated the correlation between LU-BL and prognosis HFmrEF patients. Methods This study screened consecutive hospitalized our hospital January 2015 August 2020 results at admission. admission were available 610 patients, majority diagnosed as ischemic (574, 94.1%). thus observed on Patients...
e19068 Background: Disseminated cancer cells may initially require local nutrients and growth factors to thrive survive in bone marrow. However, data on the influence of marrow derived cells(BMDC, also called stromal some publication) lung is largely unexplored. This study explore effect from biological behavior cells. Methods: The difference among cell lines their abilities metastasis was tested using SCID animal model. Supernatant aspiration(BM) condition medium human cells(BSC) were used...
7559 Background: Consolidation chemotherapy following concurrent CRT may improve systemic control and possibly prolong survival of pt with stage III NSCLC. Phase II study using docetaxel showed promising result but subsequent phase was negative. We explored the role single agent gemcitabine (G) combination carboplatin (C) as consolidation chemotherapy. Methods: Study conducted by Asian mutli-center group. Eligible criteria: IIIA/B, histologic/cytologic confirmed NSCLC, completed according to...
7352 Purpose: To investigate the efficacy and safety of Docetaxel plus cisplatin regiment every week 3 weeks in patents with non-small-cell lung cancer (NSCLC). Methods: Patients NSCLC were divided into two groups. A group: randomly assigned to receive (Taxotere) 33mg/m2 d1, 8, 15 75mg/m2 d1 4 weeks. B Results: 14 patients evaluable for efficacy. Overall response rates 50%, group 40%, 55.5% respectively. Response rate was higher than A. The major toxicities neutropenia, nausea, vomiting,...
Objective To compare the response and survival ti me of autologous peripheral blood stem cell assisted high dose chemotherapy wi th conventional in treatment small lung cancer(SCLC) to access related toxicities chemothe rapy. Methods Twenty seven patients with SCLC at age≤65?yrs entered this study. Thirteen were given cyclophosphamid e(CTX,3.0?g／m 2), etoposide(VP16,750?mg／m carboplatin (CBP,400?mg／m 2) cisplatin (DDP,60?mg／m support by G CSF (300?μg／d for 5 or 6 days) after one three cycles...